| 85.85 Real-Time Quote |  +0.98 / +1.15%Today’s Change | 42.47 Today|||52-Week Range 96.25 | +43.63% Year-to-Date |
| 2 Huge Deals as M&A Accelerates Jun 06 / MotleyFool.com | Stocks: Housing data helps rally May 28 / CNNMoney.com |
| ANAC's Discussion with FDA for Tavaborole - Analyst Blog May 30 / Zacks.com | Valeant pays $8.7 billion for Bausch & Lomb May 27 / CNNMoney.com |
| Setback for Valeant Pharma - Analyst Blog May 29 / Zacks.com | Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune |
| Valeant Pharma to Buy Bausch+Lomb - Analyst Blog May 28 / Zacks.com | Actavis: What it's like to join the Fortune 500 May 10 / Fortune |
| Previous close | 84.87 |
| Today’s open | 84.87 |
| Day’s range | 84.87 - 86.18 |
| Volume | 109,893 |
| Average volume (3 months) | 1,775,794 |
| Market cap | $25.8B |
| Dividend yield | -- |
| Earnings growth (last year) | -173.08% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +11.50% |
| Revenue growth (last year) | +43.97% |
| P/E ratio | 27.5 |
| Price/Sales | 5.15 |
| Price/Book | 6.94 |
| Today’s change | Today’s % change | |
|---|---|---|
| AGNAllergan Inc | +1.15 | +1.16% |
| ALXNAlexion Pharmaceutic... | +2.18 | +2.35% |
| SHPGShire PLC | +0.72 | +0.74% |
| VRTXVertex Pharmaceutica... | +1.25 | +1.60% |
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $3.5B |
| Annual profit (last year) | -$116.0M |
| Net profit margin | -3.27% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman & Chief Executive Officer J. Michael Pearson, MBA |
Chief Financial Officer, Director & Executive VP Howard Bradley Schiller |
Corporate headquarters Montréal, Québec |
.
